Study: Tralokinumab Shows More Frequent Injection Site React

Although injection site reactions were common occurrences in both the tralokinumab and dupilumab groups, tralokinumab caused ISRs more frequently.

Related Keywords

Italy , , Image Credit , Dermatology Unit , Naples Federico , Numerical Rating Scale , Atopic Dermatitis , Dupilumab , Tralokinumab , Injection Site Reactions ,